HLB Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate
HLB Pharmaceutical Co. Ltd cash flow reinvestment rate. HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Reinvestment Rate of 2.46x as of September 2025, reinvesting ₩4.60 Billion (capex ₩2.26 Billion plus investments ₩2.34 Billion) from operating cash flow of ₩1.86 Billion. See 047920 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of HLB Pharmaceutical Co. Ltd (2014–2024)
Cash flow reinvestment rate of HLB Pharmaceutical Co. Ltd from 2014 to 2024. Historical reinvestment intensity for HLB Pharmaceutical Co. Ltd across 3 annual periods. Explore 047920 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
HLB Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate by Year (2014–2024)
HLB Pharmaceutical Co. Ltd cash flow reinvestment rate by year from 2014 to 2024. Year-by-year capital reinvestment analysis for HLB Pharmaceutical Co. Ltd. For the full cash flow conversion analysis, see how efficiently does HLB Pharmaceutical Co. Ltd generate cash.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.24x | ₩15.35 Billion | ₩6.84 Billion | ₩3.09 Billion | ▼ -53.0% |
| 2019 | 4.77x | ₩6.46 Billion | ₩1.35 Billion | ₩1.40 Billion | ▲ +95.2% |
| 2014 | 2.44x | ₩3.77 Billion | ₩1.54 Billion | ₩2.26 Billion | — |